Norges Bank Graphite Bio, Inc. Transaction History

Norges Bank

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2023	BUY	$5.1 - $13.06 $2.83 Million - $7.24 Million	554,167 New	554,167 $2.83 Million
Q1 2022 May 09, 2022	SELL	$5.1 - $13.06 $2.83 Million - $7.24 Million	-554,167 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$8.41 - $16.71 $4.66 Million - $9.26 Million	554,167 New	554,167 $6.89 Million
Q3 2021 Nov 14, 2022	BUY	$15.81 - $28.39 $8.76 Million - $15.7 Million	554,167 New	554,167 $9.08 Million
Q3 2021 Nov 05, 2021	SELL	$15.81 - $28.39 $11.1 Million - $19.9 Million	-700,000 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$18.5 - $30.73 $13 Million - $21.5 Million	700,000 New	700,000 $21.5 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.